1. Home
  2. MMT vs CINGW Comparison

MMT vs CINGW Comparison

Compare MMT & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MMT
    SELLHOLDBUYas of 8 hours ago
  • CINGW
    SELLHOLDBUYas of 2024 years ago
  • Stock Information
  • Founded
  • MMT 1987
  • CINGW N/A
  • Country
  • MMT United States
  • CINGW United States
  • Employees
  • MMT N/A
  • CINGW 13
  • Industry
  • MMT Trusts Except Educational Religious and Charitable
  • CINGW Biotechnology: Pharmaceutical Preparations
  • Sector
  • MMT Finance
  • CINGW Health Care
  • Exchange
  • MMT Nasdaq
  • CINGW Nasdaq
  • Market Cap
  • MMT N/A
  • CINGW N/A
  • IPO Year
  • MMT N/A
  • CINGW 2021
  • Fundamental
  • Price
  • MMT $4.63
  • CINGW $0.06
  • Analyst Decision
  • MMT
  • CINGW
  • Analyst Count
  • MMT 0
  • CINGW 0
  • Target Price
  • MMT N/A
  • CINGW N/A
  • AVG Volume (30 Days)
  • MMT 86.5K
  • CINGW N/A
  • Earning Date
  • MMT 01-01-0001
  • CINGW N/A
  • Dividend Yield
  • MMT 8.58%
  • CINGW N/A
  • EPS Growth
  • MMT N/A
  • CINGW N/A
  • EPS
  • MMT 0.30
  • CINGW N/A
  • Revenue
  • MMT N/A
  • CINGW N/A
  • Revenue This Year
  • MMT N/A
  • CINGW N/A
  • Revenue Next Year
  • MMT N/A
  • CINGW N/A
  • P/E Ratio
  • MMT $15.33
  • CINGW N/A
  • Revenue Growth
  • MMT N/A
  • CINGW N/A
  • 52 Week Low
  • MMT $4.04
  • CINGW N/A
  • 52 Week High
  • MMT $4.70
  • CINGW N/A
  • Technical
  • Relative Strength Index (RSI)
  • MMT 47.45
  • CINGW N/A
  • Support Level
  • MMT $4.60
  • CINGW N/A
  • Resistance Level
  • MMT $4.64
  • CINGW N/A
  • Average True Range (ATR)
  • MMT 0.04
  • CINGW 0.00
  • MACD
  • MMT 0.00
  • CINGW 0.00
  • Stochastic Oscillator
  • MMT 46.15
  • CINGW 0.00

Stock Price Comparison Chart: MMT vs CINGW

MMT
CINGW
AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober20250.00.51.01.52.02.53.03.54.04.55.05.56.06.57.0MMT VS CINGW

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use